オプションチェーンは、NeuroSense Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、NeuroSense Therapeuticsの市場センチメントを評価します。.

NeuroSense Therapeutics (NASDAQ:NRSN) 株価情報, オプションチェーン

NeuroSense Therapeutics

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

NeuroSense Therapeutics Ltd. - Ordinary Shares

NeuroSense Therapeutics Ltd

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Mineralys Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) with a Buy and maintains $42 price target.

News

Price Target

Reiteration

Analyst Ratings

MLYS

HC Wainwright & Co. Reiterates Buy on Mineralys Therapeutics, Maintains $42 Price Target

Baird analyst Colleen Kusy maintains Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) with a Neutral and raises the price target from $3 to $4.

AGEN

Baird Maintains Neutral on Agenus, Raises Price Target to $4

Jim Cramer believes that a consistent flow of trade agreements is crucial to bolstering market confidence and allaying fears of both recession and a surge in inflation.
What Happened: In a recent post on X, Cramer asserted that a &#8220;steady drip of trade deals&#8221; might be the key ingredient to sustain the current market momentum, particularly given the limited number of institutional investors holding bullish positions.
Cramer&#8217;s commentary underscores the market&#8217;s sensitivity to global trade dynamics and their potential impact on economic stability and price levels. The implication is that positive developments on the trade front could provide the necessary reassurance for investors, outweighing prevailing concerns about a potential economic downturn and escalating inflation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bulls, right now, want nothing but a steady drip of trade deals that will make people more confident that we won&#39;t have a recession and inflation won&#39;t spike. That might just be enough to keep things going given how few institutional bulls there are
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1922199711055806937?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
In a subsequent post, Cramer also took aim at prominent bearish voices within the billionaire investor class. While not naming specific individuals in these recent posts, he emphasized the significant influence these figures wield and called for a change in their rhetoric. &#8220;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Last night i simply had to call out still one more bearish billionaire. I will tell you one thing, the words that are used by the billionaire class must change. They must learn their power for mayhem
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1922199974479008140?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Cramer&#8217;s perspective suggests a delicate balancing act for the market. While positive trade developments could act as a vital catalyst for bullish sentiment and potentially ward off recessionary pressures, the pronouncements of influential bearish investors could introduce volatility and undermine confidence.
See Also: <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war" target="_blank" rel="noreferrer noopener">S&amp;P 500 Rallies Over 3% On US-China 90-Day Tariff Truce, But Experts Warn It ‘Doesn't Guarantee A Complete Resolution Of The Trade War'</a>
Why It Matters: U.S. and China agreed on Monday to <a href="https://www.benzinga.com/markets/equities/25/05/45341884/apple-amazon-nvidia-rise-in-monday-premarket-as-us-china-agree-to-90-day-tariff-truce-neither-side-wants-a-decoupling">temporarily reduce reciprocal tariffs </a>on each other's goods for 90 days, marking a considerable easing of trade tensions. 
The recent tariff reductions between the <a href="https://www.benzinga.com/news/global/25/05/45337811/trump-announces-total-reset-as-us-china-trade-talks-aim-to-end-tariff-war">U.S. and China</a> echo a similar agreement reached with the U.K. last week, fueling optimism for a revival in global commerce and economic growth. 
However, Cramer&#8217;s call for steady progress on trade deals is vital, as the temporary nature of this 90-day deal with China doesn&#8217;t give a long-term solution.
Despite the initial positive action following the announcement, John Murillo, the chief dealing officer at B2BROKER, <a href="https://www.benzinga.com/government/regulations/25/05/45367206/sp-500-rallies-over-3-on-us-china-90-day-tariff-truce-but-experts-warn-it-doesnt-guarantee-a-complete-resolution-of-the-trade-war">emphasized</a>, "Now, while the 90-day pause is a big step towards easing tensions, it&#8217;s crucial to remember that it doesn&#8217;t guarantee a complete resolution of the trade war." 
Price Action: While the stocks rejoiced at the U.S.-China trade development on Monday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were lower in premarket on Tuesday. The SPY was down 0.22% to $581.70, while the QQQ declined 0.15% to $507.10, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data. The S&amp;P 500 futures were also trading lower on Tuesday morning.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45371290/chamath-palihapitiya-questions-ai-funding-after-swedish-bnpl-firm-klarna-rolls-back-ai-bets-startups-could-pivot-">Chamath Palihapitiya Says Swedish Fintech Company Klarna Scaling Back AI Support Is A Red Flag For Industry: Startups Could &#8216;Pivot To Simply Use AI For Narrow Use Cases&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo: Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Broad U.S. Equity ETFs

Futures

Economics

Markets

ETFs

General

Jim Cramer Says Bulls Need 'Steady Drip Of Trade Deals' To Assure Market About Recession And Inflation As S&P 500 Futures Fall After Big Rally

AFMD

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

Baird analyst Joel Beatty upgrades argenx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) from Neutral to Outperform and maintains the price target from $680 to $680.

Upgrades

ARGX

Baird Upgrades argenx to Outperform, Maintains Price Target to $680

Earnings

Earnings Beats

Earnings Misses

HUMA

UPDATE: Humacyte Q1 Adj. EPS $(0.10) Beats $(0.19) Estimate, Sales $517.00K Miss $760.33K Estimate

Mill City Ventures III (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCVT#NASDAQ">MCVT</a>) reported quarterly earnings of $0.07 per share. This is a 16.67 percent increase over earnings of $0.06 per share from the same period last year. The company reported $778.03 thousand in sales this quarter. This is a 6.56 percent decrease over sales of $832.67 thousand the same period last year.

MCVT

Mill City Ventures III Q1 GAAP EPS $0.07 Up From $0.06 YoY, Sales $778.03K Down From $832.67K YoY

Baird analyst Mircea Dobre upgrades Caterpillar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) from Neutral to Outperform and raises the price target from $309 to $395.

Baird Upgrades Caterpillar to Outperform, Raises Price Target to $395

LightInTheBox Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LITB#NYSE">LITB</a>) reported quarterly earnings of $0.01 per share. This is a 105.56 percent increase over losses of $(0.18) per share from the same period last year. The company reported $47.02 million in sales this quarter. This is a 33.93 percent decrease over sales of $71.17 million the same period last year.

LITB

LightInTheBox Holding Q1 EPS $0.01 Up From $(0.18) YoY, Sales $47.02M Down From $71.17M YoY

As of May 13, 2025, two stocks in the materials sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Crown Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCK#NYSE">CCK</a>)</h3>
<ul class="wp-block-list">
<li>On May 12, Crown Holdings reported that it has priced an offering of $700 million aggregate principal amount of 5.875% senior unsecured notes due 2033. The company's stock jumped around 14% over the past month and has a 52-week high of $99.12.</li>
<li>RSI Value: 72.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>CCK Price Action: Shares of Crown Holdings gained 0.8% to close at $97.78 on Monday.</li>
<li>Edge Stock Ratings: 78.55 Momentum score with Value at 29.80. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/cck"><img loading="lazy" decoding="async" width="482" height="172" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043838/image-137.png" alt="" class="wp-image-913115" style="width:390px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043838/image-137.png 482w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13043838/image-137-300x107.png 300w" sizes="(max-width: 482px) 100vw, 482px" /></a></figure>
<h3 class="wp-block-heading">Celanese Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>)</h3>
<ul class="wp-block-list">
<li>On May 5, Celanese posted better-than-expected results for its first quarter. "Our end-markets in the first quarter exhibited dynamics similar to the fourth quarter, and demand in our businesses developed mostly as we expected," said Scott Richardson, president and chief executive officer. "While tariffs are a constant topic, we saw no direct impact in the first quarter. No matter how the demand environment develops over the remainder of the year, our mission is unchanged." The company's stock gained around 39% over the past month and <a href="https://www.benzinga.com/quote/CE">has a 52-week high</a> of $161.94.</li>
<li>RSI Value: 70.7</li>
<li>CE Price Action: Shares of Celanese gained 6.5% to close at $54.53 on Monday.</li>
</ul>
Curious about other BZ Edge Rankings? Click here to discover <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">how similar stocks measure up</a>. 
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Trading Ideas

Top 2 Materials Stocks That May Keep You Up At Night In May

Baird analyst Mircea Dobre upgrades Terex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEX#NYSE">TEX</a>) from Neutral to Outperform and raises the price target from $48 to $66.

Baird Upgrades Terex to Outperform, Raises Price Target to $66

U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Tuesday.
Shares of 3D Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) fell sharply in today's pre-market trading after the company posted <a href="https://www.benzinga.com/quote/DDD/earnings">weaker-than-expected quarterly results.</a>
3D Systems reported quarterly losses of 21 cents per share which missed the analyst consensus estimate of losses of 14 cents per share. The company reported quarterly sales of $94.54 million which missed the analyst consensus estimate of $99.46 million.
3D Systems shares dipped 20.7% to $2.02 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Kearny Financial Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRNY#NASDAQ">KRNY</a>) shares dipped 23.5% to $5.00 in pre-market trading after gaining 3% on Monday.</li>
<li>Global IBO Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIBO#NASDAQ">GIBO</a>) declined 18.8% to $4.22 in pre-market trading after dipping over 25% on Monday.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) dipped 18.2% to $11.15 in pre-market trading. KindlyMD shares jumped 251% on Monday after the company announced a merger agreement with Nakamoto Holdings to start a Bitcoin treasury strategy.</li>
<li>Heritage Commerce Corp (NASDA: HTBK) declined 15.4% to $8.00 in pre-market trading.</li>
<li>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) fell 12.1% to $10.15 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>Exodus Movement, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXOD#NYSE">EXOD</a>) fell 11.1% to $48.25 in pre-market trading following first-quarter results.</li>
<li>NetClass Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) dipped 11% to $25.80 in pre-market trading.</li>
<li>indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) declined 11% to $2.35 in pre-market trading after the company reported worse-than-expected quarterly sales results.</li>
<li>UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) fell 9.1% to $344.44 in pre-market trading. The company announced the appointment of Stephen Hemsley as CEO.</li>
<li>Hertz Global Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) declined 8.6% to $6.34 in pre-market trading following weak quarterly results.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Movers

EXOD

GIBO

HTBK

INDI

KDLY

KRNY

NTCL

RGTI

3D Systems, Rigetti Computing, UnitedHealth Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Needham analyst Serge Belanger reiterates MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) with a Buy and maintains $66 price target.

MLTX

Needham Reiterates Buy on MoonLake, Maintains $66 Price Target

Rosenblatt analyst Catharine Trebnick maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $36 price target.

FIVN

Rosenblatt Maintains Buy on Five9, Maintains $36 Price Target

Bayer (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BAYRY#OTC">BAYRY</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.38 by 71.05 percent. This is a 15.58 percent decrease over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $14.45 billion which beat the analyst consensus estimate of $13.39 billion by 7.89 percent. This is a 3.36 percent decrease over sales of $14.95 billion the same period last year.

BAYRY

Bayer Q1 Adj. EPS $0.65 Beats $0.38 Estimate, Sales $14.45B Beat $13.39B Estimate

ITOS

Trading Halt: Halt status updated at 8:20:00 AM ET: Quotation Resumption: News and Resumption Times

Cycurion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) ("Cycurion" or the "Company"), a trusted leader in IT cybersecurity solutions and AI, announces that it has been awarded a significant contract renewal by a major state-level public higher education group. Under this renewed agreement, Cycurion will deliver comprehensive cybersecurity services to member universities and colleges within the group, ensuring they are equipped to defend their education-focused operations and digital assets against the ever-evolving landscape of cyber threats. The renewal, valued at $33 million over the five-year term, extends Cycurion's partnership through November 2030.

CYCU

Cycurion Announces $33M Contract Renewal To Deliver Comprehensive Cybersecurity Services To State-Level Public Higher Education Institutions

Biotech

ONMD

OneMedNet Adopts Expanded Capabilities Within Datavant Connect Platform To Accelerate Healthcare Data Discovery, Analytics, And Partner Assessment Processes

The MoU builds on G42's growing ecosystem as it accelerates its efforts to scale AI infrastructure and innovation
ABU DHABI, UAE, May 13, 2025 /PRNewswire/ --&nbsp;G42, the UAE-based global technology group, today announced the signing of a Memorandum of Understanding (MoU) with Cisco, the global leader in networking and security, laying the groundwork for a strategic collaboration aimed at advancing artificial intelligence (AI) innovation and infrastructure development across public and private sectors.
The agreement was presented to His Highness Sheikh Khaled bin Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi, by Peng Xiao, Group Chief Executive Officer of G42, and Chuck Robbins, Chair and Chief Executive Officer of Cisco.

CISO

G42 And Cisco Sign Strategic MOU To Extend Partnership To Drive AI Innovation And Infrastructure Development

Rosenblatt analyst Catharine Trebnick maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and maintains $445 price target.

CYBR

Rosenblatt Maintains Buy on CyberArk Software, Maintains $445 Price Target

Small Cap

Press Releases

NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement

PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape

Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug

NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting

NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates

NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment

NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update

NeuroSense Therapeutics is on Verge of Potential Blockbuster Pharma Deal as ALS Drug Shows 58% Survival Improvement

NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch

NRSN

D. Boral Capital

Alliance Global Partners

Screenshot 2024-10-17 at 10.10.15 PM

NeuroSense Advances Plans For Early Commercialization Of Potentially Groundbreaking ALS Treatment In Canada, Targeting A $100M+ Market

Comments

NeuroSense Therapeutics

NeuroSense Therapeutics (NRSN) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル